|
|
|
|
|
|
Sponsors and Collaborators: |
NCI - Center for Cancer Research-Medical Oncology National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00019461 |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of carboxyamidotriazole in treating patients with refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.
Condition | Intervention | Phase |
Fallopian Tube Cancer Ovarian Cancer Peritoneal Cavity Cancer |
Drug: carboxyamidotriazole Procedure: chemotherapy |
Phase II |
MedlinePlus related topics: | Cancer Ovarian Cancer |
Drug Information available for: | L 651582 |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase II Trial of Orally Administered CAI for Patients With Persistent or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
Study Start Date: | April 1998 |
OBJECTIVES:
OUTLINE: Patients receive oral carboxyamidotriazole daily beginning on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 19-40 patients will be accrued for this study within 2 years.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Measurable disease by physical exam, radiography, peritoneoscopy, or laparoscopy
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Pulmonary:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
United States, Maryland | |||||
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support | |||||
Bethesda, Maryland, United States, 20892-1182 |
NCI - Center for Cancer Research-Medical Oncology |
National Cancer Institute (NCI) |
Study Chair: | Mahrukh Hussain, MD | NCI - Center for Cancer Research-Medical Oncology |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000066216, NCI-98-C-0012, NCI-T97-0112 |
First Received: | July 11, 2001 |
Last Updated: | October 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00019461 |
Health Authority: | United States: Federal Government |
|
|
|
|
|